People always wanted it all with this stock : complaints about it being undercapitalised, but then critical of why the study is only smaller pilot one in Georgia to prove the therapeutic concept! I mean c'mon.
Holders are getting a crack at multiple trials in diff treatment synergies. GK said from the outset, objective is to raise just enough to test the NOX66 efficacy. Results coming in are showing he knows what he is doing.
Wouldn't be crazy to think that even this interim data would excite enough to get potential partners sniffing around.
